Fulgent Genetics (FLGT) Liabilities and Shareholders Equity (2015 - 2026)

Fulgent Genetics has disclosed Liabilities and Shareholders Equity across 12 years of filings, most recently posting $1.2 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $1.2 billion, down 4.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.8 billion (down 2.2% YoY), and the FY2025 annual result was $1.2 billion, down 0.53% from the prior year.
• Liabilities and Shareholders Equity came in at $1.2 billion for Q1 2026 at Fulgent Genetics, down from $1.2 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.5 billion in Q1 2022 to a low of $93.2 million in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $1.2 billion (2024), against an average of $1.2 billion.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 92.71% in 2022 and jumped 1225.0% in 2023, its largest moves.
• Fulgent Genetics' Liabilities and Shareholders Equity stood at $93.2 million in 2022, then surged by 1225.0% to $1.2 billion in 2023, then slipped by 1.24% to $1.2 billion in 2024, then retreated by 0.53% to $1.2 billion in 2025, then declined by 4.71% to $1.2 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.2 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.